Hong Dai
Beijing Hospital · Liaoning Provincial Corps Hospital of the Chinese People's Armed Police · Peking Union Medical College
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hong Dai as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:58 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07185841 · Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)Fujian Haixi Pharmaceuticals Co., Ltd. · recruiting · Wet Age-related Macular Degeneration (AMD) · principal investigator
- N/ANCT06410443 · Efficacy and Safety of Local Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal InjuryGeneral Hospital of Shenyang Military Region · recruiting · Radiation-Induced Intestinal Injury · principal investigator
- Ph3NCT05439629 · Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular DegenerationBio-Thera Solutions · completed · Neovascular (Wet) Age-related Macular Degeneration · principal investigator
- Ph2NCT04667897 · 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · completed · Branch Retinal Vein Occlusion · principal investigator
- Ph4NCT02905409 · Study of Surgery in Patients With Idiopathic Macular HolePeking University People's Hospital · unknown · Idiopathic Macular Hole, Surgery · principal investigator
- Ph4NCT01574430 · Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)Peking University People's Hospital · completed · Central Serous Chorioretinopathy · principal investigator
- Ph3NCT00320762 · Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing HospitalPro Top & Mediking Company Limited · completed · Glaucoma, Pterygium · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 27 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:58 UTC. The ranking covers the 200 most relevant of 185 PubMed records, and a shared surname and initials can bring in a namesake. All 185 on PubMed
- Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.Lancet Oncol · 2013386 citationsRCR 10.6
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.J Hematol Oncol · 2020282 citationsRCR 10.4
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.Clin Cancer Res · 2017281 citationsRCR 8.3
- Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.Blood · 2020274 citationsRCR 10.1
- 273 citationsRCR 34.0
- Behavioural nudges increase COVID-19 vaccinations.Nature · 2021272 citationsRCR 17.2
- Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.Protein Cell · 2018269 citationsRCR 7.8
- l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.J Clin Invest · 2019265 citationsRCR 11.8
- Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.Clin Cancer Res · 2018230 citationsRCR 6.6
- 226 citationsRCR 7.1